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Methylmalonic  acidemia  with  emergency  hypertension
Acidemia  metilmalónica  con  hipertensión  de  emergencia-
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tDear Editor,
Methylmalonic acidemia (MMA)  is a heterogeneous disor
der of propionate metabolism. MMA  is caused by deﬁcienc
of the mitochondrial enzyme, methylmalonyl-CoA mutase
apoenzyme activity (MUT) or defective in adenosylcobalamin
(coenzyme) synthesis.1 The most patients with cblA and hal
patients with cblB forms of MMA  are responsive to vita
min  B12.2,3 Clinical manifestation of MMA  may be acut
or chronic. The acute form of the disease occurs durin
infancy and even as early as the second day of life with
poor feeding, vomiting, dehydration, weight loss, tempera
ture instability, lethargy, hypotonia, seizure and progressin
to coma. Laboratory ﬁndings include: metabolic acidosis
ketosis, hypoglycemia, hyperlactatemia, hyperammonemia
pancytopenia.4
Deﬁnitive diagnosis of isolated MMA  is based on analy
sis of organic acids in plasma and/or urine; however geneti
testing diagnosis in some condition is accessible to conﬁrm
the diagnosis of isolated MMA.  Below, we  describe the pre
sentation and management of two cases of MMA with sever
hypertention.
The ﬁrst case was a 46-day-old girl, admitted to the emer
gency department because of generalized edema and sever
hypertension. She was born from consanguineous parents a
term with a birth weight 2.600 kg. She had frequent vomi
ting in 9th day of life. Edema of hands and feet appeared in
39th day of life. On admission, she had SBP 130 mmHg  (abov
99th), DBP 75 mmHg  (above 99th), periorbital and legs pittin
edema and respiratory distress. Laboratory ﬁndings included
microscopic hematuria, massive proteinuria, hypoalbomine
mia, pancytopenia and high anion gap metabolic acidosis.
The patient was managed by nephrologists with diagnosi
of congenital nephrotic syndrome. Angiography of abdomina
aorta and renal artery were normal. She had brain atro
phy and supra and infra tentorial ventricolomegaly in brain
CT scan and left ventricular hypertrophy in echocardiogra-
phy. Abdominal sonography was normal but both kidneyswere seen larger than normal. Bone marrow aspiration (BMA
was performed because of pancytopenia which was nor
mal. Patient’s hypertension did not respond to Losartan
Hydralazine, Captopril and Amlodipine. Metabolic consulting
and then metabolic tests due to refractory metabolic acidosi
was done. The patient with suspected organic aciduria wa
treated with hydroxycobalamin 1 mg  daily, biotin 10 mg  daily
and l-carnitine 50 mg/kg/day. She had high level of glycine
in blood amino acid chromatography but ammonia, lactate
serum B12 and hemocystein were normal. Methylmalonic
aciduria conﬁrmed with high level of urine methlmalonic acid
and increased serum level of propionyl carnitine. We  have
increased the dose of B12 up to 2 mg  IM daily but unfortunately
the patient died.
The second case was a 45-day-old boy admitted from
the emergency ward with complaints of anemia, respiratory
distress and severe hypertension. He was born from non
consanguineous parents at term with a birth weight 2.800 kg
The ﬁrst baby of the family had died at the age of 5-months due
to propionic aciduria. On examination he had respiratory dis
tress (RR = 67), SBP 134 mmHg  (above 99th) and DBP 78 mmHg
(above 99th) and mild pitting edema in legs. Laboratory result
included: high anion gap metabolic acidosis, pancytopenia
hypoalbominemia, proteinuria, and microscopic hematuria
Lactate, ammonia, serum B12, serum hemocystein and othe
electrolytes were normal but serum glycine was increased
Renal artery disorder has been excluded by Doppler sonogra
phy. Abdominal sonography was normal but both kidneys had
upper normal size and increased cortical echogenicity. BMA
was performed because of pancytopenia which was normal
According to the familial history and our previous case, afte
sending samples for urine organic acid, acylcarnitine proﬁle
and chromatography of serum amino acid, B12 2 mg  IM daily
carnitine 50 mg/kg/day, biotin 10 mg  daily and low protein die
was started for the patient. His blood pressure was refractory
to all of anti-hypertensive drugs such as Hydralazine, Capto-
pril, Labetalol. Methylmalonic aciduria conﬁrmed by increased
of urine methylmalonic acid and serum propionyl carnitine.
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Despite early treatment of methylmalonic acid even without
waiting for tests result, the patient died.
Chronic renal disease is a life-threatening complication of
MMA  and ﬁnally leads to dialysis or kidney transplantation.
Renal impairment most occurs in patients with mut (0) and
cblB mutation.5 The mechanism of renal injury in MMA is
still unknown. Proximal tubular disorder is a main pathogenic
mechanism of MMA-associated kidney disease.6 A recent case
study has reported 2 cases of MMA  associated with hemolytic
uremic syndrome (HUS) association which revealed that prob-
able pathogenesis of thrombotic microangiopathy could be
related to the increase of plasma methylmalonic acid and
homocysteine levels.7
In the current study, the two mentioned patients had MMA
that conﬁrmed with assessment of urine organic acid and
acylcarnitine proﬁle. They had just renal involvement that
their symptom and signs were started during infancy that was
refractory to all of the treatment and despite early treatment
in the one of them, they died.
In summary, in each case with hematuria, proteinuria,
nephrotic syndrome, unexplained hypertension or renal fail-
ure of unknown origin especially in pediatric patients,
metabolic screening and urinary organic acid analysis should
be carried out as soon as possible.
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Glomerulonefritis  necrosante  en  el síndrome  por consumo
de cocaína  y  levamisol
Necrotising  glomerulonephritis  in  levamisole-contaminated
cocaine  use
Sr. Director:
Espan˜a es el país con mayor incidencia de consumo de
co 1,2
ta
re
u
ca
ló
leucocitoclástica o una vasculopatía trombótica; 2) leucope-
nia y neutropenia, y 3) positividad de distintos parámetros
inmunológicos2,3 (tabla 1). La nefropatía por C/L se halla ape-
n
glcaína en adultos , y en la última década se han incremen-
do las partidas de cocaína adulteradas con levamisol2,3. En
lación con la toma de cocaína/levamisol (C/L) se describe
n síndrome diferenciado por: 1) lesiones cutáneas purpúri-
s, necróticas o equimóticas, en tronco, extremidades y
bulo de las orejas; el sustrato histológico es una vasculitis
d
sa
enas documentada.
Describimos el caso de un paciente que desarrolló una
omerulonefritis necrosante, con insuﬁciencia renal y sín-
rome nefrótico, asociada al consumo de C/L. Hasta donde
bemos esta sería la primera publicación con biopsia renal
 nuestro país.
